


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A chemical compound of formula (I):



(I)

wherein:

R₁ and R₂ are independently selected from hydrogen and alkyl;

R₃ is alkyl;

R₄ and R₅ are selected from hydrogen and alkyl;

R₆ and R₇ are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, alkylsulfonyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and

A is a 5-membered ring ~~optionally~~ containing one heteroatom selected from N, O or S, wherein the atoms of the ring A, other than the unsaturated carbon atoms of the phenyl ring to which the ring A is fused, are saturated or unsaturated, or a pharmaceutically acceptable salt, addition compound or prodrug thereof.

2. (Original) A compound according to claim 1 wherein R₁ and R₂ are independently selected from H and lower alkyl.
3. (Original) A compound according to claim 1 wherein R₁ and R₂ are hydrogen.
4. (Previously Presented) A compound according to claim 1 wherein R₃ is loweralkyl.

5. (Previously Presented) A compound according to claim 1 wherein R₃ is methyl.
6. (Previously Presented) A compound according to claim 1, wherein R₄ and R₅ are independently selected from hydrogen and lower alkyl.
7. (Previously Presented) A compound according to claim 1, wherein R₆ and R₇ are independently selected from hydrogen and lower alkyl.
8. (Previously Presented) A compound according to claim 1, wherein one or more of R₄ to R₇ is/are hydrogen.
9. (Canceled)
10. (Previously Presented) A compound according to claim 1, wherein A is partially unsaturated.
11. (Canceled)
12. (Canceled)
13. (Currently Amended) A compound according to claim 1, wherein A is selected from the group consisting of cyclopentenyl, dihydrofuranyl, and dihydrothienyl.
14. (Previously Presented) A compound according to claim 1 wherein the compounds of formula (I) are selected from the group consisting of (S)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine, (S)-1-(2,3,7,8-tetrahydrothieno[2,3-g]indol-1-yl)-2-propylamine, [2S,3(R or S)]-1-(3-ethyl-2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine and [2S,3(S or R)]-1-(3-ethyl-2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine.
- 15 – 23. (Canceled)
24. (Currently Amended) A method of treatment of obesity disorders ~~of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea~~, comprising administering to a

patient in need of such treatment an effective dose of a compound of formula (I) as set out in claim 1.

25. (Canceled)

26. (Withdrawn) A method according to claim 24, wherein said treatment is prophylactic treatment.

27. (Canceled)

28. (Previously Presented) A pharmaceutical composition comprising a compound of formula (I) as set out in claim 1 in combination with a pharmaceutically acceptable carrier or excipient.

29. (Previously Presented) A method of making a pharmaceutical composition, comprising combining a compound of formula (I) as set out in claim 1 with a pharmaceutically acceptable carrier or excipient.

30. (Previously Presented) A method of treating a condition treatable by agonism of the 5HT₂ receptor comprising administering a compound according to claim 1.

31 – 36. (Canceled)